Ropinirole for the treatment of earlyParkinson disease -: A 12-month experience
Ropinirole for the treatment of earlyParkinson disease -: A 12-month experience
复制标题
DOI：
10.1001/archneur.55.9.1211
复制
发表时间：
1998-09-01
影响因子：
--
通讯作者：
Hauser, RA
中科院分区：
文献类型：
--
作者：
Sethi, KD;O'Brien, CF;Hauser, RA
Objective: To evaluate ropinirole hydrochloride as dopaminergic monotherapy in patients with early Parkinson disease.Design: A 6-month extension of a double-blind, placebo-controlled study.Setting: Ambulatory care at 22 different sites in the United States.Patients: Patients who successfully completed the initial 6-month study could enter the 6-month extension study (ropinirole, n=70; placebo, n=77).Intervention: Use of ropinirole or placebo therapy.Main Outcome measures: The efficacy variables were the number of patients who successfully completed the 12-month study and did not require supplemental levodopa, the number of patients requiring supplemental levodopa, and the proportion of patients having an insufficient therapeutic response.Results: Significantly fewer ropinirole-treated patients met criteria for insufficient therapeutic response (23 [19.8%] of 116) or required the initiation of levodopa therapy (22 [19%] of 116) compared with placebo-treated patients (60 [48%] of 125 patients for insufficient therapeutic response; 57 [45.6%] of 125 patients for additional levodopa). Significantly more ropinirole-treated patients (51 [44.0%] of 116) successfully completed the 12-month study and did not require supplemental levodopa compared with placebo-treated patients (28 [22.4%] of 125). The incidence of adverse experiences and patient withdrawals was low.Conclusion: Ropinirole was effective and well tolerated as monotherapy for 12 months in patients with early Parkinson disease.
